Finance

Hot Watch List: Apple Inc. (NASDAQ:AAPL), Twitter Inc (NYSE:TWTR), Gilead Sciences, Inc. (NASDAQ:GILD), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Apple Inc. (NASDAQ:AAPL)’s resurgent stock may have as much to do with financial engineering as the company’s technological wizardry. Monday marked Apple Inc. (NASDAQ:AAPL)’s first stock split in nine years, a move designed to make it more affordable to buy shares of the iPhone and iPad maker. Apple Inc. (NASDAQ:AAPL) stock performance was 1.60% in last session and finished the day at $93.70. Traded volume was 75.41million shares in the last session and the average volume of the stock remained 70.11million shares. The beta of the stock remained 0.93. Apple Inc. (NASDAQ:AAPL) insider ownership is 0.04%.

Twitter Inc (NYSE:TWTR), LinkedIn, Facebook, eBay, Google and Apple Inc. (NASDAQ:AAPL), all of which pay more than $5,000 a month, or $60,000 annually if these were full time jobs. Twitter Inc (NYSE:TWTR) rose 3.42 percent to $34.47 Monday on volume of 23.40million shares. The intra-day range of the stock was $33.09 to $34.55. Twitter Inc (NYSE:TWTR) has a market capitalization of $20.31billion.

Gilead Sciences, Inc. (NASDAQ:GILD) which makes almost half its revenue from hepatitis C drug Sovaldi, closed about 4% lower. One in 100 Americans have chronic hep C infections, according to the Centers for Disease Control. Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on June 09, 2014 reported a decrease of -4.11% to the closing price of $79.00. Its fifty two weeks range is $46.70 -$84.88. The total market capitalization recorded $121.33billion. The overall volume in the last trading session was 23.33million shares. In its share capital, GILD has 1.54billion outstanding shares.

The stock price of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) another small company developing hepatitis C drugs, climbed more than 47 percent on speculation that it would be bought by a company that lost out in the bidding for Idenix. On Monday, shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) advanced 47.57% to close the day at $4.25. Company monthly performance is recorded as 68.65%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) quarterly revenue growth is 28.40%.